最近の記事
- 2024/10/24
- 250129ネットセミナー次世代ゼブラフィッシュ創薬の展開
- 2024/07/05
- 新しいハイスループット個別ゼブラフィッシュ腎毒性スクリーニングシステムの創生と応用
- 2024/07/05
- 第51回日本毒性学会学術年会
- 2024/06/10
- 新しいハイスループット個別ゼブラフィッシュ腎毒性スクリーニングシステムの創生と応用
- 2024/06/06
- DXAIゼブラフィッシュ創薬の発展
- 2024/06/05
- AIゼブラフィシュ発生毒性試験の基盤技術開発
- 2024/06/04
- プレシジョン蛋白尿定量スクリーニング法開発
- 2024/06/03
- in vivo 血漿蛋白蛍光色素ZMB741論文が、アクセプトされました。
| 2019/03/14 |
|
Dravet 症候群ゼブラフィッシュモデルによる抗てんかん薬in vivoフェノミックスクリーニングシステム
三重大学大学院医学系研究科システムズ薬理学岡村実奈さんが、第９２回日本薬理学会年会で、報告予定です。
in vivo Phenomic Screening System for Antiepileptic Drugs using Dravet Syndrome Zebrafish Model
Epilepsy is a common chronic neurological disease affecting almost 1 million people in Japan and 50 million people worldwide. Despite availability of more than two dozen FDA-approved antiepileptic drugs, one-third of patients fail to receive adequate seizure control. Specifically, pediatric genetic epilepsies are often the most severe, debilitating and pharmaco-resistant forms of epilepsy.
The discovery of epilepsy associated genes suggests varied underlying pathologies and opens the door for development of precision medicine for each genetic epilepsy. Over 80% of patients diagnosed with Dravet syndrome carry a de novo mutation within the voltage-gated sodium channel gene SCN1A and these patients suffer with drug resistant and life-threatening seizures. Here we have developed zebrafish models for Dravet syndrome featuring inactivation of SCN1A with an emphasis on phenomics. we will also report recent drug screening efforts using our models with a focus on assay protocols and predictive pharmacological profiles. As the discovery and development phase rapidly moves from the lab-to-the-clinic for Dravet syndrome, it is hoped that this zebrafish-based drug discovery strategy offers a platform for how to approach any genetic epilepsy.
関連リンク
